Bioscience Pharma Partners

Bioscience Pharma Partners is a private clinical-stage biotechnology company developing therapies for chronic neuroinflammation and neurodegenerative or central nervous system disorders. The company's lead asset, BPP-1001, is a patented repurposed oral small molecule designed to inhibit the leukotriene pathway, with a particular focus on reducing neuroinflammation-mediated damage in the CNS. Its development strategy has emphasized the FDA 505(b)(2) pathway and potential use in traumatic brain injury, post-concussion syndrome, and broader neurodegenerative indications such as Alzheimer's disease and Parkinson's disease. The company also works with external diagnostic and analytics collaborators to support clinical development in CNS disease. Bioscience Pharma Partners presents itself as a virtual biopharmaceutical company headquartered in Scottsdale, Arizona.